Transcript Document

GENTA
(GNTA)
www.genta.com
Recent stock price: 12.44 (2/17/04 close)
52-wk range: 5.50 – 17.65
Market cap: 923 Mil
Diluted EPS: - 0.66
Revenue: 5.2 Mil ttm
Expenses: - 66 Mil ttm
Net income: - 61 Mil ttm
Revenue Growth: 2337% ttm
Est. target price: 16.25
Founded: 1988 Berkley Heights, NJ
Employees: 96
Analyst
upgrades
Genasense
P-III
results
State
visit
Analyst
down
grades
NDA
filed
Analyst
reports
Analyst recommendations: neutral/mkt perform “ 2.0 / 5.0“ (1= Strong buy, 5 = Strong sell)
Products
Discovery Formulation Ph1 Ph2 Ph3 Market
Genasense
Ganite
Androgenics
Oral Gallium
Decoy
Genasense—Antisense Bcl-2 to inhibit tumor growth. Overexpression of Bcl-2 is a
major contributing factor to the development of drug resistance in cancer patients
undergoing chemotherapy, radiation, or monoclonal antibody treatment. Most
tumors express high levels of Bcl-2, therefore inactivation of Bcl-2 is a feasible
target to sensitize cancer cells to these therapies. Phase III trials show 2-month
increase in survival rate for melanoma patients. NDA filed in Dec 2003 for malignant
melanoma and has fast-track designation. Phase I and II trials are ongoing for CLL,
MML (2004 NDA, orphan drug status), prostate (2005), NSCLC (2006), NHL (2006),
colon (2007) and breast (2007). $477 Mil collaboration with Aventis to develop
Genasense.
Ganite—FDA approved drug consisting of elemental gallium delivered intravenously
for the treatment of cancer-related hypercalcemia (excessive buildup of calcium in
the bloodstream). Because gallium also acts as a ribonucleotide reductase inhibitor,
an IND has been filed for Ganite treatment of Non-Hodgkin’s Lymphoma.
Oral Gallium—Gallium also incorporates into metabolically active bone where it can inhibit bone resorption. An
oral formulation is being developed for low-dose extended-use treatment to maintain bone integrity over longterm periods. Currently in Preclinical development.
Androgenics—Small molecule compounds that inhibit testosterone production for hormone-dependent prostate
cancer treatment. Currently in Preclinical development.
CREBP Decoy—Modified strands of DNA or RNA bases with increased half-life that act as a decoy for cyclic AMP
response element (CRE)-binding protein. Preclinical studies indicate this drug can selectively inhibit cancer cell
growth.
GNTA vs. ISIS
GNTA vs. LORFF
GNTA vs. BTK
DIRECT COMPETITOR COMPARISON
GNTA
ISIS
LORFF
INDUSTRY
Market Cap:
1.0B
480 M
137 M
215 M
Employees:
96
523
52
117
Rev. Growth (ttm):
2337%
51%
Gross Margin (ttm):
100%
100%
88%
95%
EBITDA (ttm):
-58.7M
-68.7M
-16.4M
-18.0M
Net Income (ttm):
-59.9M
-86.1M
-17.0M
-20.9M
EPS (ttm):
-0.81
-1.56
-0.11
-0.71
PS (ttm):
190.1
7.4
273.5
13.7
GNTA = Genta Inc.
ISIS = Isis Pharmaceuticals
LORFF.OB = Lorus Therapeutics Inc
11%